Myelodysplastic syndromes

Common Name(s)

Myelodysplastic syndromes, MYELODYSPLASTIC SYNDROME

Myelodysplastic syndromes (MDS) are a rare group of blood disorders characterized by abnormal development of blood cells within the bone marrow. Individuals with MDS have abnormally low blood cell levels (low blood counts). Signs and symptoms associated with MDS include dizziness, fatigue, weakness, shortness of breath, bruising and bleeding, frequent infections, and headaches. In some cases, MDS may progress to bone marrow failure or an acute leukemia. The exact cause of MDS is unknown. It sometimes runs in families, but no disease-causing gene has been identified. Treatment depends on the affected individual's age, general health, and type of MDS and may include red cell and/or platelet transfusions and antibiotics.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

http://www.aamds.org/

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

http://www.nbmtlink.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Myelodysplastic syndromes" returned 700 free, full-text research articles on human participants. First 3 results:

Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes.
 

Author(s): Sriram Sundaravel, Ryan Duggan, Tushar Bhagat, David L Ebenezer, Hui Liu, Yiting Yu, Matthias Bartenstein, Madhu Unnikrishnan, Subhradip Karmakar, Ting-Chun Liu, Ingrid Torregroza, Thomas Quenon, John Anastasi, Kathy L McGraw, Andrea Pellagatti, Jacqueline Boultwood, Vijay Yajnik, Andrew Artz, Michelle M Le Beau, Ulrich Steidl, Alan F List, Todd Evans, Amit Verma, Amittha Wickrema

Journal: Proc. Natl. Acad. Sci. U.S.A.. 2015 Nov;112(46):E6359-68.

 

Anemia is the predominant clinical manifestation of myelodysplastic syndromes (MDS). Loss or deletion of chromosome 7 is commonly seen in MDS and leads to a poor prognosis. However, the identity of functionally relevant, dysplasia-causing, genes on 7q remains unclear. Dedicator of ...

Last Updated: 20 Nov 2015

Go To URL
Brevundimonas diminuta bacteremia in a man with myelodysplastic syndromes.
 

Author(s): Huiling Cao, Min Li, Xuewen Yang, Chunbing Zhang

Journal: Indian J Pathol Microbiol. ;58(3):384-6.

 

Brevundimonas diminuta are ubiquitous in the environment, but are infrequently isolated from clinical samples. Here we report a case of B. diminuta bacteremia in a man with myelodysplastic syndromes (MDS) at a teaching hospital in China and review the previously reported cases. The ...

Last Updated: 15 Aug 2015

Go To URL
Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias.
 

Author(s): Yutaka Kohgo, Akio Urabe, Yurdanur Kilinç, Leyla Agaoglu, Krzysztof Warzocha, Koichi Miyamura, Lay Cheng Lim, Sabine Glaser, Candace Wang, Wieslaw Wiktor-Jedrzejczak

Journal: Acta Haematol.. 2015 ;134(4):233-42.

 

Iron overload in transfusion-dependent patients with rare anemias can be managed with chelation therapy. This study evaluated deferasirox efficacy and safety in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) or other rare anemias. A 1-year, open-label, multicenter, ...

Last Updated: 31 Mar 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Myelodysplastic syndromes" returned 125 free, full-text review articles on human participants. First 3 results:

Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation.
 

Author(s): Olatoyosi Odenike, Francesco Onida, Eric Padron

Journal: Am Soc Clin Oncol Educ Book. 2015 ;():e398-412.

 

Myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a variable propensity for leukemic transformation. In recent years there has been an explosion of information on the ...

Last Updated: 21 May 2015

Go To URL
Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.
 

Author(s): Hironori Harada, Yuka Harada

Journal: Cancer Sci.. 2015 Apr;106(4):329-36.

 

Myelodysplastic syndromes (MDS) are defined as stem cell disorders caused by various gene abnormalities. Recent analysis using next-generation sequencing has provided great advances in identifying relationships between gene mutations and clinical phenotypes of MDS. Gene mutations ...

Last Updated: 22 Apr 2015

Go To URL
Frequent chromatin rearrangements in myelodysplastic syndromes--what stands behind?
 

Author(s): E Pagáčová, M Falk, I Falková, E Lukášová, K Michalová, A Oltová, I Raška, S Kozubek

Journal: Folia Biol. (Praha). 2014 ;60 Suppl 1():1-7.

 

Myelodysplastic syndromes (MDS) represent a clinically and genetically heterogeneous group of clonal haematopoietic diseases characterized by a short survival and high rate of transformation to acute myeloid leukaemia (AML). In spite of this variability, MDS is associated with typical ...

Last Updated: 5 Nov 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
 

Status: Recruiting

Condition Summary: Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Secondary Myelodysplastic Syndrome

 

Last Updated: 12 Apr 2016

Go to URL
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
 

Status: Recruiting

Condition Summary: Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts in Transformation; Secondary Myelodysplastic Syndrome

 

Last Updated: 26 Apr 2016

Go to URL
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
 

Status: Recruiting

Condition Summary: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome

 

Last Updated: 12 Jan 2016

Go to URL